Immunoglobulin chimeric monomer-dimer hybrids

Details Immunoglobulin chimeric monomer-dimer hybrids Immunoglobulin chimeric monomer-dimer hybrids

2011-01-04

2011-01-04

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated via claimed linking group, bond, chelating agent,...

C424S133100, C424S134100, C424S178100, C530S387100, C530S387300, C530S391100, C530S391700, C530S391900

Reexamination Certificate

active

07862820

ABSTRACT:
The invention relates to a chimeric monomer-dimer hybrid protein that comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first polypeptide chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

REFERENCES:
patent: 3941763 (1976-03-01), Sarantakis
patent: 4695623 (1987-09-01), Stabinsky
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4831119 (1989-05-01), Nordfang et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 5077204 (1991-12-01), Brake et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5162220 (1992-11-01), Oshima et al.
patent: 5175096 (1992-12-01), Höök et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5189015 (1993-02-01), Höök et al.
patent: 5234830 (1993-08-01), Oshima et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5482858 (1996-01-01), Huston et al.
patent: 5579277 (1996-11-01), Kelly
patent: 5585089 (1996-12-01), Queen et al.
patent: 5591573 (1997-01-01), Whalen et al.
patent: 5605689 (1997-02-01), Ammann
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648240 (1997-07-01), Hook et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5885821 (1999-03-01), Magota et al.
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6015881 (2000-01-01), Kang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6060065 (2000-05-01), Barney et al.
patent: 6060613 (2000-05-01), Hattori et al.
patent: 6068973 (2000-05-01), Barney et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6093799 (2000-07-01), Li et al.
patent: 6184344 (2001-02-01), Kent et al.
patent: 6228983 (2001-05-01), Barney et al.
patent: 6280994 (2001-08-01), Sheppard
patent: 6281331 (2001-08-01), Kang et al.
patent: 6310180 (2001-10-01), Tam
patent: 6310183 (2001-10-01), Johannessen et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6329176 (2001-12-01), Woldike et al.
patent: 6469136 (2002-10-01), Bray et al.
patent: 6475491 (2002-11-01), Johnson et al.
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6518013 (2003-02-01), Barney et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 7084109 (2006-08-01), Dennis et al.
patent: 7348004 (2008-03-01), Peters et al.
patent: 7385032 (2008-06-01), Tschopp et al.
patent: 7404956 (2008-07-01), Peters et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2003/0119727 (2003-06-01), Dennis et al.
patent: 2003/0180287 (2003-09-01), Gambotz et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2004/0077022 (2004-04-01), Feige et al.
patent: 2004/0110929 (2004-06-01), Bjorn et al.
patent: 2005/0027109 (2005-02-01), Mezo et al.
patent: 2005/0037941 (2005-02-01), Munoz, Jr. et al.
patent: 2005/0037947 (2005-02-01), Bitonti et al.
patent: 2005/0147618 (2005-07-01), Rivera et al.
patent: 2005/0281829 (2005-12-01), Hehir et al.
patent: 2007/0172928 (2007-07-01), Peters et al.
patent: 2008/0249288 (2008-10-01), Mezo et al.
patent: 2045869 (1991-12-01), None
patent: 0 325 262 (1989-07-01), None
patent: 0 464 533 (1992-01-01), None
patent: 0 589 577 (1997-02-01), None
patent: 2 641 468 (1990-07-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-02-01), None
patent: WO 89/10134 (1989-11-01), None
patent: WO 90/11364 (1990-10-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 96/22024 (1996-07-01), None
patent: WO 99/04813 (1999-02-01), None
patent: WO 00/06605 (2000-02-01), None
patent: WO 00/18881 (2000-05-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 01/02440 (2001-01-01), None
patent: WO 01/03737 (2001-01-01), None
patent: WO 01/36637 (2001-05-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/83526 (2001-11-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO 02/18417 (2002-03-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO 02/089828 (2002-11-01), None
patent: 03/077834 (2003-09-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/004798 (2004-01-01), None
patent: WO 2004/006962 (2004-01-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
patent: WO 2005/051289 (2005-06-01), None
US 6,020,459, 02/2000, Barney et al. (withdrawn)
Pipe et al. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics: Targets & Therapy 2009, vol. 3, p. 117-125.
Growe et al. Hemophilia and Von Willebrand'S Disease:2. Management. Canadian Medical Association Journal, Jul. 15, 1995, vol. 153, No. 2, p. 147-157.
Duga et al. Factor XI deficiency. Seminars in Thrombosis and Hemostasis. Jun. 2009. vol. 35, No. 4, p. 416-425. Abstract only provided.
Menegatti et al. Factor X deficiency. Seminars in Thrombosis and Hemostasis. Jun. 2009, vol. 35, No. 4, p. 407-415. Abstract only provided.
Aruffo et al., “CD44 Is the Principal Cell Surface Receptor for Hyaluronate,”Cell61:1303 (1990).
Ashkenazi et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA88:10535 (1991).
Bennett et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. Biol. Chem. 266:23060 (1991).
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1Fragments,”Science229:81 (1985).
Byrn et al., “Biological properties of a CD4 immunoadhesin,”Natur, 344:667 (1990).
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature337:525 (1989).
Chalupny et al., “T-cell activation molecule 4-1BB binds to extracellular matrix proteins,”Proc. Natl. Acad. Sci. USA89:10360 (1992).
Dawson et al., “Synthesis of Native Proteins by Chemical Ligation,”Annu. Rev. Biochem. 69:923 (2000).
Gascoigne et al., “Secretion of a chimeric T-cell receptor-immunoglobulin protein,”Proc. Natl. Acad. Sci. USA84:2936 (1987).
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,”J. Immunol. 148(5):1547 (1992).
Kurschner et al., “Construction, Purification, and Characterization of New Interferon γ (IFNγ) Inhibitor Proteins,”J. Biol. Chem267:9354 (1992).
Lesslauer et al., “Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality,”Eur. J. Immunol. 21:2883 (1991).
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,”J. Exp. Med173:721 (1991).
Linsley et al., “CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7,”J. Exp. Med. 174:561 (1991).
Louis et al., “Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity,”J. Biol. Chem. 276:(31)29485 (2001).
Peppel et al., “A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity,”J. Exp. Med. 174:1483 (1991).
Ridgway

Affiliated with

Also associated with

Rating

Immunoglobulin chimeric monomer-dimer hybrids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoglobulin chimeric monomer-dimer hybrids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin chimeric monomer-dimer hybrids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2670515